The clinical use of connective tissue substitutes is controversial. This viewpoint aims at outlining and highlighting some of the notable work in the field and at encouraging debate.
Hyaluronate is a glycosaminoglycan with a repeating disaccharide structure that is composed of D-glucuronic acid in linkage to N-acetyl-Dglucosamine. Free 53 Other workers have shown partial protective effects of systemic administration of glycosaminoglycans after meniscectomy in a canine model of osteoarthritis. 54 Radiolabelled material in the bloodstream after intra-articular injection of hyaluronate suggests that further study of systemic events might assist our understanding of joint physiology.'2 Apparently, hyaluronate is synthesised in synovium, partly broken down within the joint,'and then travels by the lymphatic system to be taken up mainly by lymph nodes where it is degraded. Alternatively, it may continue into the bloodstream to be degraded in the liver, kidney, and spleen. Turnover in the bloodstream is normally in the range of 03 to 1-0 g/min/kg body weight, and the half life of free unbound hyaluronate is two days.55 On The possibilities of using hyaluronate after total joint replacement, nerve repair, tissue resection, trauma, and cartilage repair are subjects for future study.
Conclusions A recent symposium article described the clinical uses of crosslinked forms of hyaluronate which have been given the generic name of Hylans.80 The procedures described include socalled 'space-making viscosurgical tools', 'viscosurgical implants', 'arthroscopic viscosurgery', 'matrix engineering', 'promotion of tissue regeneration', and 'tissue augmentation'. The nature of these effects has been discussed in this article. There is now enough evidence to stimulate interest in large scale, controlled clinical investigations into the effects of the administration of hyaluronate and other connective tissue substitutes. These trials might also permit evaluation of different regimens, molecular weights, and concentrations of such substitutes.
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